Naoko Kanda

5.8k total citations
159 papers, 4.2k citations indexed

About

Naoko Kanda is a scholar working on Dermatology, Immunology and Rheumatology. According to data from OpenAlex, Naoko Kanda has authored 159 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Dermatology, 72 papers in Immunology and 41 papers in Rheumatology. Recurrent topics in Naoko Kanda's work include Dermatology and Skin Diseases (81 papers), Psoriasis: Treatment and Pathogenesis (42 papers) and Allergic Rhinitis and Sensitization (30 papers). Naoko Kanda is often cited by papers focused on Dermatology and Skin Diseases (81 papers), Psoriasis: Treatment and Pathogenesis (42 papers) and Allergic Rhinitis and Sensitization (30 papers). Naoko Kanda collaborates with scholars based in Japan and United States. Naoko Kanda's co-authors include Shinichi Watanabe, Hidehisa Saeki, Yayoi Tada, Shinichi Watanabe, Teppei Hagino, Tetsuya Tsuchida, Kunihiko Tamaki, Toshihiko Hoashi, Eita Fujimoto and Shinichi Sato and has published in prestigious journals such as The Journal of Immunology, Biochemistry and Biochemical and Biophysical Research Communications.

In The Last Decade

Naoko Kanda

148 papers receiving 4.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Naoko Kanda Japan 38 1.7k 1.4k 836 686 561 159 4.2k
Tetsuya Honda Japan 37 2.4k 1.5× 2.7k 1.9× 819 1.0× 598 0.9× 991 1.8× 133 5.5k
J.‐P. Ortonne France 43 1.7k 1.0× 2.7k 1.9× 760 0.9× 563 0.8× 348 0.6× 140 5.3k
Daniel N. Sauder Canada 39 1.8k 1.1× 1.8k 1.3× 963 1.2× 305 0.4× 414 0.7× 122 5.2k
J. Michelle Kahlenberg United States 39 2.7k 1.6× 744 0.5× 1.7k 2.0× 1.4k 2.1× 363 0.6× 127 4.9k
J.‐P. Ortonne France 30 2.0k 1.2× 1.5k 1.1× 498 0.6× 556 0.8× 314 0.6× 69 3.4k
Emmanuel Contassot Switzerland 34 1.5k 0.9× 975 0.7× 1.3k 1.5× 264 0.4× 218 0.4× 61 3.7k
Akio Mori Japan 41 1.4k 0.9× 484 0.3× 1.7k 2.1× 426 0.6× 1.2k 2.1× 290 6.1k
Matthias Schmuth Austria 45 906 0.5× 2.8k 2.0× 1.9k 2.3× 231 0.3× 566 1.0× 159 6.0k
Kayoko Matsunaga Japan 32 592 0.4× 1.8k 1.2× 723 0.9× 574 0.8× 307 0.5× 225 4.5k
Tao Zheng United States 33 1.5k 0.9× 979 0.7× 1.2k 1.4× 314 0.5× 1.5k 2.7× 61 4.9k

Countries citing papers authored by Naoko Kanda

Since Specialization
Citations

This map shows the geographic impact of Naoko Kanda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoko Kanda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoko Kanda more than expected).

Fields of papers citing papers by Naoko Kanda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoko Kanda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoko Kanda. The network helps show where Naoko Kanda may publish in the future.

Co-authorship network of co-authors of Naoko Kanda

This figure shows the co-authorship network connecting the top 25 collaborators of Naoko Kanda. A scholar is included among the top collaborators of Naoko Kanda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoko Kanda. Naoko Kanda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hagino, Teppei, Hidehisa Saeki, Eita Fujimoto, & Naoko Kanda. (2025). Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice. Annals of Dermatology. 37(2). 86–86.
2.
Sugitani, Iwao, et al.. (2025). A Case of Stevens–Johnson Syndrome Induced by Selpercatinib. The Journal of Dermatology. 52(6). 1066–1069.
3.
Hagino, Teppei, Akihiko Uchiyama, Sei‐ichiro Motegi, et al.. (2025). 24-Week Real-World Effectiveness and Safety of Lebrikizumab for Atopic Dermatitis in Japan: An Analysis Stratified by Prior Systemic Therapy. Dermatitis. derm20250045–derm20250045. 1 indexed citations
4.
Hagino, Teppei, et al.. (2025). Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan. Dermatitis. derm20250004–derm20250004. 5 indexed citations
5.
Hagino, Teppei, Hidehisa Saeki, Eita Fujimoto, & Naoko Kanda. (2025). Clinical and Laboratory Indexes for Predicting Early and Late Responders to Lebrikizumab in Atopic Dermatitis: A Prospective Cohort Observational Study. Dermatitis. derm20250118–derm20250118. 1 indexed citations
6.
7.
Hagino, Teppei, Hidehisa Saeki, Eita Fujimoto, & Naoko Kanda. (2025). Long‐term real‐world effectiveness of deucravacitinib in psoriasis: A 52‐week prospective study stratified by prior apremilast or biologic therapy. The Journal of Dermatology. 52(4). 634–641. 1 indexed citations
8.
Hagino, Teppei, Hidehisa Saeki, Eita Fujimoto, & Naoko Kanda. (2024). Predictive Factors for Long-Term High Responders to Upadacitinib Treatment in Patients with Atopic Dermatitis. Dermatitis. 36(1). 62–71. 8 indexed citations
9.
Hagino, Teppei, Hidehisa Saeki, Eita Fujimoto, & Naoko Kanda. (2024). Effectiveness of long‐term bimekizumab treatment and predictive factors for responders in moderate‐to‐severe psoriasis: A 52‐week real‐world study. The Journal of Dermatology. 52(2). 317–328. 6 indexed citations
10.
Ichiyama, Susumu, Michiko Ito, Taeang Arai, et al.. (2024). Real-World Screening Data for Liver Fibrosis in Psoriasis Patients Treated with Biologics. Journal of Nippon Medical School. 91(6). 534–540.
11.
Hagino, Teppei, Hidehisa Saeki, Eita Fujimoto, & Naoko Kanda. (2024). Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan. Journal of Dermatological Treatment. 35(1). 2307489–2307489. 16 indexed citations
12.
Hagino, Teppei, Hidehisa Saeki, Eita Fujimoto, & Naoko Kanda. (2024). Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study. Journal of Dermatological Treatment. 35(1). 2344591–2344591. 19 indexed citations
13.
Miyazaki, Shun, Susumu Ichiyama, Michiko Ito, et al.. (2023). Change in Antinuclear Antibody Titers during Biologic Treatment for Psoriasis. Journal of Nippon Medical School. 90(1). 96–102. 1 indexed citations
14.
Hagino, Teppei, Hidehisa Saeki, & Naoko Kanda. (2023). Biomarkers and Predictive Factors for Treatment Response to Tumor Necrosis Factor-α Inhibitors in Patients with Psoriasis. Journal of Clinical Medicine. 12(3). 974–974. 16 indexed citations
15.
Hagino, Teppei, Hidehisa Saeki, Eita Fujimoto, & Naoko Kanda. (2023). Background factors predicting the occurrence of herpes zoster in atopic dermatitis patients treated with upadacitinib. The Journal of Dermatology. 50(10). 1301–1312. 13 indexed citations
16.
Ito, Michiko, Susumu Ichiyama, Toshihiko Hoashi, et al.. (2021). Severe Psoriasis Successfully Treated with Brodalumab after Eradication of Hepatitis C Virus with Glecaprevir and Pibrentasvir: A Case Report. Annals of Dermatology. 33(6). 593–593. 1 indexed citations
17.
Fukuyasu, Atsuko, Masahiro Kamata, Carren Sy Hau, et al.. (2021). Serum interleukin‐10 level increases in patients with severe signs or symptoms of herpes zoster and predicts the duration of neuralgia. The Journal of Dermatology. 48(4). 511–518. 10 indexed citations
18.
Morita, Takashi, et al.. (2020). Dietary habits in Japanese patients with chronic spontaneous urticaria. Australasian Journal of Dermatology. 61(3). e333–e338. 2 indexed citations
19.
Kanda, Naoko, et al.. (2019). Linear IgA bullous dermatosis associated with ulcerative colitis: A case report and literature review. Australasian Journal of Dermatology. 61(1). e82–e86. 14 indexed citations
20.
Kanda, Naoko, Masahiro Kamata, Yayoi Tada, et al.. (2011). Human β-defensin-2 enhances IFN-γ and IL-10 production and suppresses IL-17 production in T cells. Journal of Leukocyte Biology. 89(6). 935–944. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tetsuya Honda Breakdown of academic impact, for papers by J.‐P. Ortonne Breakdown of academic impact, for papers by Daniel N. Sauder Breakdown of academic impact, for papers by J. Michelle Kahlenberg Breakdown of academic impact, for papers by J.‐P. Ortonne Breakdown of academic impact, for papers by Emmanuel Contassot Breakdown of academic impact, for papers by Akio Mori Breakdown of academic impact, for papers by Matthias Schmuth Breakdown of academic impact, for papers by Kayoko Matsunaga Breakdown of academic impact, for papers by Tao Zheng
Rankless by CCL
2026